Astal Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astal Laboratories Ltd is ₹ 61.52 as of 05 May 15:30 . The P/E Ratio of Astal Laboratories Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Astal Laboratories Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Astal Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Astal Laboratories Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Astal Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Astal Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Astal Laboratories Ltd

Astal Laboratories Limited was formerly incorporated as a public company limited by shares on August 03, 1993 in the name of Macro International Limited.
The Company was taken over under SEBI takeover guidelines in 2022 and the main objects of the Company was changed to 'Manufacture and Sales of Pharmaceutical Intermediates and Bulk Drugs'.
Subsequently the name of the Company was changed to Astal Laboratories Limited in May, 2024.
The Company is now a subsidiary of Aceso Research Labs LLP. The Company was promoted by the Kanpur based business house of Parasrampurias.
The Company set up a departmental store at Plaza Kalpana, Birhana Road, Kanpur, offering products such as readymade garments, electronic items, leather items, stationery, books, fast food centre etc. During 1996-97, the departmental store project succeeded, only Saree Division and Archies Card Division was in operation.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Astal Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Astal Laboratories Ltd or Sanofi India Ltd?

Market cap of Astal Laboratories Ltd is 259 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Astal Laboratories Ltd and Sanofi India Ltd?

The stock performance of Astal Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astal Laboratories Ltd and Sanofi India Ltd?

As of May 5, 2026, the Astal Laboratories Ltd stock price is INR ₹61.52. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Astal Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Astal Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.